Figure 2.

Design of the seven core clinical trials. (A) TICORA study (Grigor et al 2004)²⁶; (B) CAMERA study (Verstappen et al 2007)²⁷; (C) Fransen et al 2005²⁸; (D) Symmons et al 2005²⁹; (E) Edmonds et al 2007 (abstract)³¹; (F) van Tuyl et al 2008³⁰; and (G) Stenger et al 1998.³² Intensive and routine treatment arms are displayed, red arrows mark the scheduled intervals for target assessment. Table 1 specifies the targets of trials A–G. AZA, Azathioprine; CAMERA, Computer Assisted Management in Early Rheumatoid Arthritis; CRP, C reactive protein; DAS, Disease Activity Score; DMARD, disease-modifying antirheumatic drug; HCQ, hydroxychloroquine; IFX, ifosfamide; LDA, low disease activity; LEF, leflunomide; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; sc, subcutaneous; SJC, swollen joint count; sod., sodium; SPZ, sulfinpyrazone; TICORA, tight control of rheumatoid arthritis.